Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | C1S | P09871 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 4/20 | 0.33 |
| ▸ | CTSS | P25774 | 4/20 | 0.33 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | CTSC | P53634 | 3/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839561 | 0.76 | C1S (0.46) | KMT2AGAAHTTC1SFEN1 | |
| SCHEMBL5840151 | 0.76 | C1S (0.62) | C1S | |
| SCHEMBL5840373 | 0.72 | PNP (0.34) | KMT2ACA2ALDH1A1MAPTNPSR1 | |
| SCHEMBL948704 | 0.72 | — | — | |
| SCHEMBL12914081 | 0.71 | ALDH1A1 (0.33) | KMT2AGAAHTTPIK3CDPIK3CA | |
| SCHEMBL12914023 | 0.70 | F2 (0.40) | KMT2AGAAHTTPIK3CDPIK3CA | |
| SCHEMBL947376 | 0.70 | VCAM1 (0.37) | HTTALDH1A1MAPTNPSR1 | |
| SCHEMBL12913986 | 0.69 | KMT2A (0.36) | KMT2AKIF18ACA2ALDH1A1 | |
| SCHEMBL12914127 | 0.69 | LMNA (0.32) | KMT2AGAAHTTPIK3CDPIK3CA | |
| SCHEMBL30990704 | 0.69 | KMT2A (0.64) | KMT2AGAAHTTCA2CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100412073-C | Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | DIMENSIONAL PHARM INC (US) | 2008-08-20 | — | — | CN | disclosed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109354-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| CN-1665800-A | Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | DIMENSIONAL PHARM INC (US) | 2005-09-07 | — | — | CN | disclosed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | KMT2A 4363/4885GAA 3751/4885HTT 584/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | KMT2A 4508/4885GAA 4035/4885HTT 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.